>> How big a deal is this litigation, anyhow? <<
OSIP just licensed the "platform". I don't know if that originates from Pfizer-acquired confidence or from faith in a work-around. The Solvay program is supposedly free of infringement issues, as screening was done in Europe. To me, this means that the company should be shopped, from a position of strength, in Europe. Perhaps the office action (PTO) will free up interest in the U.S.
One can conclude (and hopefully be correct), from the Nature Biotechnology publications, that both Apex and SSCL work. It seems, to me, that a "phenotyping" company could combine the KDUS screens with their procedures to create, on the cheap, a wonderful little genomics operation.
Wouldn't the Sangamo business plan be much more attractive if they had (1) potential "either/or" milestone and royalty flow from Solvay/proprietary OSIP, and (2) a convenient screening capacity for orphan receptor ligands?
As I mentioned earlier, I have not been able to find any "guidance" on royalty levels from OSIP. I am assuming, for my models, a rate of 6%.
WO9918211
YEAST CELLS EXPRESSING MODIFIED G PROTEINS AND METHODS OF USE
THEREFOR
WO9902699
KDS PROTEIN KINASE MOLECULES AND USES RELATED THERETO
WO9813513
METHODS AND COMPOSITIONS FOR IDENTIFYING RECEPTOR EFFECTORS
WO9845231
SUPPORTS FOR SOLID PHASE SYNTHESIS
WO9941385
MEKK1 PROTEINS AND FRAGMENTS THEREOF FOR USE IN REGULATING
APOPTOSIS
WO9947686
HUMAN MEKK PROTEINS, CORRESPONDING NUCLEIC ACID MOLECULES,
AND USES THEREFOR
WO9854116
SYNTHESIS AND USE OF THIOPHENE- AND PYRROLE-BASED
HETEROAROMATIC COMPOUNDS
WO9854208
CONFORMATIONALLY CONSTRAINED PEPTIDOMIMETICS AS beta -TURN
TEMPLATES AND MODULATORS OF SH3 DOMAINS
WO9958670
AGS PROTEINS AND NUCLEIC ACID MOLECULES AND USES THEREFOR
WO9962518
PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
WO9963099
FUNCTIONAL EXPRESSION OF ADENOSINE RECEPTORS IN YEAST |
